Apollo Therapeutics Group Ltd. and Sunshine Lake Pharma Co. Ltd. inked a potential $938 million licensing deal for APL-18881 (HEC-88473), Sunshine’s dual fibroblast growth factor 21 ...

Inno Supps’ Trim Biome™ GLP-1 is designed to support the body’s natural production of GLP-1 through a unique blend of ...

Coya Therapeutics (COYA) releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan….”Given my recent ...

The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

One big idea has loomed over healthcare stocks over the past two years: Demand for the new GLP-1 weight loss medicines from ...

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective treatment options for obesity. Medications such as semaglutide (branded as ...

Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.

GLP-1 agonist medications have gained significant attention, especially for their role in weight management and type 2 diabetes treatment. While these medications have been around for nearly 20 ...

The category is expected to scale to $8.7 billion by 2027. The market for GLP-1 agonist drugs also continues to grow and is expected to exceed $100 billion by 2030. NBJ's report aims to educate ...